Toho Holdings Company Limited operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Toho Holdings Company Limited with three other
drug stores in Asia:
Vital KSK Holdings Incorporation
sales of 559.71 billion Japanese Yen [US$5.13 billion]
of which 95%
was Pharmaceuticals Sales),
Suzuken Co., Ltd.
(2.13 trillion Japanese Yen [US$19.55 billion]
of which 93%
was Pharmaceutical Wholesale Business), and
Hokuyaku Takeyama Holdings, Inc
(235.15 billion Japanese Yen [US$2.16 billion]
of which 68%
was Pharmaceutical Business).
During the year ended March of 2019, sales at
Toho Holdings Company Limited were ¥1.22 trillion (US$11.21 billion).
a very small
increase of 0.7%
versus 2018, when the company's sales were ¥1.21 trillion.
Despite this increase, sales are still
below the level achieved in 2017, when Toho Holdings Company Limited
reported sales of ¥1.23 trillion.
The sales level in 2019 was fairly close to the level five years ago: in 2014, Toho Holdings Company Limited had sales
of ¥1.19 trillion.
Sales of Pharmaceutical Wholesale Business saw an increase
1.3% in 2019, from
¥1.11 trillion to ¥1.13 trillion.
Not all segments of Toho Holdings Company Limited experienced an increase in sales in 2019:
sales of Information Equipment Sales fell 21.0% to ¥1.16 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).
Toho Holdings Company Limited also experienced decreases in sales in
Dispensing Pharmacy Business (down 4.8% to ¥92.93 billion)
Institutional Support for Clinical Trial (down 13.3% to ¥280.00 million)